intelligence360
  • SUBSCRIBE
  • About us
  • Video News Daily
  • Contact Us
  • Search Icon

intelligence360

The Intelligent News Source

Japanese-Founded Regulatory T-cell Reprogramming Company RegCell Secures $45.8M in Funding and Completes U.S. Headquarters Transition

Japanese-Founded Regulatory T-cell Reprogramming Company RegCell Secures $45.8M in Funding and Completes U.S. Headquarters Transition

March 31, 2025 Craig Etkin

Funding includes $8.5M from an oversubscribed seed financing with up to $37.3M in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring Japan’s commitment to breakthrough therapies

Funding will advance RegCell’s first-in-class epigenetic regulatory T-cell reprogramming platform to first-in-human clinical trials in 2025

Strategic move to a U.S.-based entity will accelerate clinical development, global partnerships, and commercialization opportunities for company founded by pioneering immunologist

EMERYVILLE, Calif., March 18, 2025 /PRNewswire/ — RegCell, Inc., a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T-cells (Tregs), today announced the closing of an oversubscribed seed round and its transition to a U.S.-based company.

The $8.5 million seed financing was co-led by The University of Tokyo Edge Capital Partners (UTEC) and Fast Track Initiative (FTI), with participation from Celadon Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC), and Kyoto University Innovation Capital (Kyoto i-Cap).

In addition, RegCell was awarded up to $37.3 million in non-dilutive funding (¥5.6 Billion) from Japan’s Agency for Medical Research and Development (AMED). This funding will support the development of RegCell’s epigenetic reprogramming platform through clinical proof-of-concept and further validates RegCell’s technology and Japan’s commitment to innovation.

This additional capital will support RegCell’s plans to initiate a first-in-human trial in 2025 targeting an antigen-specific autoimmune indication. AMED’s support will fund IND-enabling studies, GMP optimization, and establishing clinical proof-of-concept in the US.

RegCell’s scientific founder, Professor Shimon Sakaguchi, whose pioneering research led to the discovery of regulatory T cells (Tregs) and their essential function in maintaining immunological self-tolerance, stated, “This funding accelerates RegCell’s mission of developing potentially curative treatments for autoimmune diseases and transplantation and provides a very efficient path to clinical proof of concept.”

Furthermore, the strategic U.S. corporate restructuring transitions RegCell to a U.S.-based corporation, broadening access to international talent, capital, and partnerships, enhancing R&D capabilities, and expanding business development outreach to global partners. RegCell will continue to operate its core scientific operations to access world-class scientific capabilities in Japan while leveraging its U.S. footprint to access regulatory and commercialization expertise that tends to be scarce in the emerging Japanese biotech ecosystem.

“This funding, combined with our ambitious corporate restructuring, represents a crucial milestone in RegCell’s evolution as it propels us forward in our mission to bring groundbreaking immunology therapies to the forefront of global healthcare,” said Dr. Michael McCullar, CEO of RegCell. “This financial support and U.S.-based restructuring are not just strategic steps; they are forces that will drive both our clinical development and business success in the years ahead.”

On behalf of existing investors, Dr. Atsushi Usami, Partner and Board Director at UTEC and RegCell, shared the following statement “I am truly delighted that the innovative Treg cell therapy, developed by Prof. Sakaguchi, is progressing towards transformative clinical milestones with the support of Japan’s AMED, a team of seasoned drug development experts—primarily from the U.S.—and new investors committed to our shared vision for RegCell. This therapy has the potential to bring relief to countless patients suffering from immune diseases worldwide. I sincerely hope it reaches clinical practice in the most appropriate and widespread manner as soon as possible.”

Dr. Koji Yasuda, Principal at Fast Track Initiative, will join the RegCell Board and added the following statement: “Regulatory T-cells play a critical role in maintaining immune tolerance, yet translating their biology into effective therapies has been challenging. RegCell’s differentiated approach has the potential to address a broad range of autoimmune diseases and beyond. We are excited to support this breakthrough Japanese science developed by Prof. Sakaguchi and his team and help bring its impact to the U.S. and global markets.”

About RegCell 

RegCell is a global biotechnology company pioneering cell therapies for autoimmune diseases and transplantation. With newly established U.S. headquarters and deep roots in Japan’s renowned scientific community, RegCell is founded on the pioneering discoveries of Co-Founder Professor Shimon Sakaguchi, a leader in regulatory T-cell (T-reg) biology.

RegCell has developed a proprietary, best-in-class platform to generate stable, epigenetically reprogrammed, antigen-specific Tregs designed to restore immune tolerance. Current autoimmune treatments rely on immunosuppression, leading to persistent adverse events and the need for life-long therapy. RegCell’s platform overcomes key barriers that have hindered the development of autoimmune cell therapies by addressing unknown or multiple pathogenic antigens. Unlike genetic modification approaches, RegCell’s epigenetic reprogramming technology simplifies manufacturing, enhances safety, and enables scalable production, bringing the promise of transformative cell therapies to a broad spectrum of autoimmune patients, including those with diseases driven by undefined autoantigens.

Driven by a vision to redefine self-tolerance, RegCell is committed to delivering safe, life-changing cell therapies that can restore immune tolerance, reverse autoimmune disorders, and overcome challenges in transplantation.  

For more information, visit http://www.regcellbio.com/

About AMED 

The Japan Agency for Medical Research and Development (AMED), established in 2015, is a government agency dedicated to accelerating medical innovation and strengthening Japan’s global competitiveness in healthcare. AMED supports integrated research and development across the medical spectrum, from basic science to clinical applications, to translate cutting-edge discoveries into real-world treatments. As part of this mission, AMED launched the V-ECO (Strengthening Program for Pharmaceutical Startup Ecosystem) grant to foster the growth of Japan’s biotech sector. This program provides substantial non-dilutive funding to startups developing innovative therapies, contingent upon investment from pre-certified venture capital firms. By supporting early-stage pharmaceutical development, including non-clinical and clinical studies, V-ECO aims to accelerate breakthrough medical innovations and position Japan as a leader in biotech entrepreneurship.

Media Contact:
Ignacio Guerrero-Ros, Ph.D.
Russo Partners LLC
ignacio.guerrero-ros@russopartnersllc.com  

Investor Contact:
James Ahlers
RegCell, Inc.
james.ahlers@regcellbio.com

SOURCE RegCell, Inc.

Copyright © 2025 Cision US Inc.


Venture Capital
California, Cision, Emeryville, PRNewswire, RegCell, Venture Capital

Post navigation

NEXT
Outdoor creator platform Popfly™ secures $2 million in oversubscribed seed financing to scale intelligent creator economy solutions
PREVIOUS
Austin Independent School District to spend $131,682,419.00 to occupy 242,623 square feet of space in Austin Texas.
Comments are closed.
Subscribe for FREE!

intelligence360

intelligence360
Source: http://go.intelligence360.io/ and https://intelligence360.news/

Kimberly-Clark Corporation, one of the world's leading manufacturers of personal care and hygiene products, will establish an $800 million advanced manufacturing facility in Trumbull County, bringing an anticipated 491 new high-quality jobs. For Kimberly-Clark, this new facility would be its first in Ohio and represents not just a strategic expansion, but a decisive step in doubling down on growth in the American market. Spread across more than one million square feet, the Warren facility will provide the manufacturing capacity needed to unleash future growth for Kimberly-Clark’s fastest-growing personal care categories that include Baby & Child Care and Adult & Feminine Care. Warren is in geographic proximity to roughly 117 million consumers and will serve as a strategic hub for the Northeast and Midwest regions. Construction is expected to begin this month and will take up to two years.

In a statement Tamera Fenske, chief supply chain officer at Kimberly-Clark said, “Our investment in Warren is a pivotal step forward in our North America business and strategy.” “By establishing a new, state-of-the-art manufacturing facility in Ohio, we’re enhancing our ability to serve millions of consumers across the Midwest and Northeast with greater speed, agility, and resilience. It’s a once-in-a-career opportunity to build a facility from the ground up that reflects the future of manufacturing, and with the support of local partners like JobsOhio, the Department of Development, Lake to River, Western Reserve Port Authority, and local governments, we have the unique opportunity to create high-quality jobs and long-term economic impact in the region.”

Based in Dallas and employing 46,000 people in 34 countries, the company’s portfolio of brands also includes Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll. Its products are sold in more than 175 countries and territories.
Source: http://go.intelligence360.io/ and https://intelligence360.news/

Snorkel AI announced general availability of two new product offerings on the Snorkel AI Data Development Platform: Snorkel Evaluate and Snorkel Expert Data-as-a-Service. These launches advance its mission to turn knowledge into specialized AI—helping teams move from prototype to production at scale by leveraging Snorkel AI’s programmatic data development technology. In addition, Snorkel AI announced it has raised $100 million in Series D funding at a $1.3 billion valuation, led by Addition. This new funding will fuel continued research and innovation in evaluating and tuning specialized AI systems with expert data.


In a statement Alex Ratner, Co-founder and CEO of Snorkel AI said, “We are seeing a surge of momentum around agentic AI, but specialized enterprise agents aren’t ready for production in most settings.” “Enterprises need domain-specific data and expertise to make this a reality. We’re excited to deliver on this need and help AI innovators develop expert data to bring their LLM and agentic systems into production with our new offerings, which round out Snorkel’s unified AI data development stack.”

Snorkel AI is building the Snorkel AI Data Development Platform for evaluating and tuning specialized AI at scale. Snorkel AI’s offerings, including Snorkel Evaluate and Snorkel Expert Data-as-a-Service, accelerate evaluation and tuning of specialized AI systems with expert data—helping teams move from prototype to production at scale by leveraging Snorkel AI’s programmatic data development technology. Launched out of the Stanford AI Lab, Snorkel AI’s platform is used in production by Fortune 500 companies, including BNY, Wayfair, and Chubb, as well as across the U.S. federal government, including the U.S. Air Force.
Source: http://go.intelligence360.io/ and https://intelligence360.news/

TicketManager, a global leader in event ticket and guest management solutions for the corporate enterprise, today announced Valeas Capital Partners, a growth-oriented private-equity firm, has acquired a majority stake in the company. Under the terms of the agreement, Valeas is committing $110 million to support TicketManager’s strategic growth plans. TicketManager Co-Founder and CEO Tony Knopp and COO Ken Hanscom will retain a minority interest in the Company. Founded in 2007, TicketManager is the category leader in providing software and services to manage end-to-end event ticket workflow and guest experiences. Serving as the central hub and system of record for data-driven organizations, the platform streamlines every step of the ticket management process. Every year, companies spend more than $600 billion on customer entertainment, yet 43% of corporate tickets are never used and fewer than 20% of organizations leverage modern software to optimize those investments and mitigate compliance risk.

In a statement Tony Knopp, CEO and Co-Founder of TicketManager said, “Live events are an important investment for businesses of all sizes. Whether major global sponsorships, naming rights for stadiums, luxury suites or even a few season tickets for the local team, companies use them to attract and keep customers while building their brands. But in today’s market, many companies struggle with growing pressure to show the value of their ticket spending.” “We knew there was a better way, and that’s why we created TicketManager – to make company tickets easy and prove the return on investment with cutting edge technology and services.”

TicketManager is a leading event- and guest-management platform that empowers companies to make client entertainment easy and drive greater return on investment. It offers convenient and simple technology to manage corporate sports and entertainment tickets, create exceptional guest life-cycle experiences, and measure effectiveness. TicketManager is trusted by more than 500 global brands including Verizon, FedEx, Adidas, Anheuser-Busch, and Mastercard.
Load More... Subscribe

Categories

Recent Posts

  • Bespoken Spirits Announces Successful Close of Series-C Funding Round June 9, 2025
  • Bito Raises $5.7M Seed Extension to Expand AI Code Review Platform with Codebase Awareness June 9, 2025
  • Pillar Biosciences Raises $34.5M in Funding June 9, 2025
  • CloudZero Raises $56M Series C To Redefine Cloud Cost Optimization In The AI Era June 9, 2025

Archives

© 2025   Copyright SI360 Inc. All Rights Reserved.